Business
Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’
Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancerEuropean registration completed and commercial rollout
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancerEuropean registration completed and commercial rollout underway across multiple territoriesFDA clinical study process to be launched for U.S. regulatory approval BERKELEY, Calif. and MAINZ, Germany, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the Company’s ordinary shares have commenced trading on The Nasdaq Capital Market (the “Nasdaq”) under the ticker symbol “MYNZ”. “Transitioning to the public markets via a Nasdaq listing is an important milestone for the Company, as it provides a platform to facilitate growth, and to ultimately execute on our mission to become a leader in developing next generation early detection diagnostics for multiple cancer indications,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We are excited to ramp-up commercial activities across Europe for ColoAlert and look forward to commencing U.S. clinical and regulatory activities for this cost-effective, highly efficacious, and easy-to-use detection test for colorectal cancer.” About ColoAlertColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the European Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.*Dollinger MM et al. (2018) About Colorectal CancerColorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival ...